Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab for Renal Function in Sickle Cell Disease (STEADFAST)
NCT04053764Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of crizanlizumab in sickle cell disease (SCD), sickle cell nephropathy (SCN), sponsored by Novartis. Started Dec 2019; status: completed.
02
Drugs
crizanlizumab
03
Conditions
sickle cell disease (SCD)sickle cell nephropathy (SCN)
Beyond the preview
Go deeper on NCT04053764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04053764.